$-0.63 EPS Expected for Ardelyx (ARDX), Westchester Capital Management Decreased By $428,464 Its Rite Aid Corp. (RAD) Stake

July 18, 2017 - By Hazel Jackson

Westchester Capital Management Llc decreased Rite Aid Corp. (RAD) stake by 2.11% reported in 2016Q4 SEC filing. Westchester Capital Management Llc sold 53,558 shares as Rite Aid Corp. (RAD)’s stock declined 41.75%. The Westchester Capital Management Llc holds 2.48 million shares with $20.44M value, down from 2.53M last quarter. Rite Aid Corp. now has $2.41 billion valuation. The stock rose 6.93% or $0.16 reaching $2.47. About 180,724 shares traded. Rite Aid Corporation (NYSE:RAD) has declined 55.18% since July 18, 2016 and is downtrending. It has underperformed by 71.88% the S&P500.

Analysts expect Ardelyx Inc (NASDAQ:ARDX) to report $-0.63 EPS on August, 14.They anticipate $0.20 EPS change or 24.10% from last quarter’s $-0.83 EPS. After having $-0.59 EPS previously, Ardelyx Inc’s analysts see 6.78% EPS growth. It closed at $5.8 lastly. It is down 19.22% since July 18, 2016 and is downtrending. It has underperformed by 35.92% the S&P500.

Among 6 analysts covering Ardelyx Inc (NASDAQ:ARDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ardelyx Inc had 8 analyst reports since August 18, 2015 according to SRatingsIntel. BTIG Research initiated the stock with “Buy” rating in Friday, December 18 report. The rating was maintained by Citigroup on Wednesday, August 10 with “Buy”. Cantor Fitzgerald maintained the shares of ARDX in report on Wednesday, May 31 with “Buy” rating. JMP Securities maintained the shares of ARDX in report on Wednesday, March 9 with “Market Outperform” rating. The firm has “Buy” rating by Ladenburg Thalmann given on Thursday, March 31. BTIG Research initiated Ardelyx Inc (NASDAQ:ARDX) on Tuesday, September 22 with “Buy” rating. The stock has “Buy” rating by Wedbush on Thursday, September 3.

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $277.23 million. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal diseases. It currently has negative earnings. It operates through the research, development and commercialization of biopharmaceutical products segment.

Westchester Capital Management Llc increased Hewlett Packard Enterprise Company (Put) stake by 3.09 million shares to 4.46M valued at $103.11 million in 2016Q4. It also upped Ashland Global Holdings Inc. (Put) stake by 681,800 shares and now owns 756,000 shares. Isle Of Capri Casinos Inc. (NASDAQ:ISLE) was raised too.

Investors sentiment decreased to 0.92 in 2016 Q4. Its down 0.26, from 1.18 in 2016Q3. It worsened, as 67 investors sold RAD shares while 114 reduced holdings. 39 funds opened positions while 128 raised stakes. 598.79 million shares or 0.81% more from 593.98 million shares in 2016Q3 were reported. Capstone Invest Advisors Ltd has invested 0.04% in Rite Aid Corporation (NYSE:RAD). Allstate invested in 4.51 million shares. Perella Weinberg Prns Cap Mngmt Lp has invested 0.93% in Rite Aid Corporation (NYSE:RAD). Css Ltd Il, Illinois-based fund reported 386,600 shares. Bluecrest Cap Mngmt Limited accumulated 0.1% or 216,922 shares. Jefferies Gp Ltd Llc has 128,267 shares for 0.01% of their portfolio. Gam Ag holds 42,680 shares. New York-based Glg Limited Liability Corp has invested 0.03% in Rite Aid Corporation (NYSE:RAD). Nordea Investment Mgmt has 23,355 shares for 0% of their portfolio. Jpmorgan Chase & has 0.03% invested in Rite Aid Corporation (NYSE:RAD) for 13.10 million shares. Grimes And has invested 0.01% of its portfolio in Rite Aid Corporation (NYSE:RAD). Communication Of Vermont, Vermont-based fund reported 5,000 shares. Principal Financial Grp holds 69,469 shares. Fairfield Bush & Co invested 0.05% in Rite Aid Corporation (NYSE:RAD). Savings Bank Of America Corporation De reported 0.01% stake.

Among 11 analysts covering Rite Aid (NYSE:RAD), 3 have Buy rating, 2 Sell and 6 Hold. Therefore 27% are positive. Rite Aid had 16 analyst reports since August 6, 2015 according to SRatingsIntel. As per Friday, August 14, the company rating was upgraded by Vetr. On Thursday, October 29 the stock rating was downgraded by Credit Suisse to “Neutral”. As per Thursday, October 29, the company rating was downgraded by Goldman Sachs. The firm earned “Buy” rating on Thursday, August 6 by Vetr. JP Morgan downgraded the stock to “Neutral” rating in Friday, November 13 report. As per Wednesday, April 26, the company rating was downgraded by Guggenheim. Mizuho maintained Rite Aid Corporation (NYSE:RAD) on Thursday, September 17 with “Buy” rating. The stock of Rite Aid Corporation (NYSE:RAD) earned “Hold” rating by Deutsche Bank on Friday, April 8. Bank of America initiated Rite Aid Corporation (NYSE:RAD) rating on Thursday, August 13. Bank of America has “Buy” rating and $11 target. On Friday, June 30 the stock rating was reinitiated by Evercore with “Underperform”.

Analysts await Rite Aid Corporation (NYSE:RAD) to report earnings on September, 28. They expect $-0.02 EPS, down 166.67% or $0.05 from last year’s $0.03 per share. After $-0.05 actual EPS reported by Rite Aid Corporation for the previous quarter, Wall Street now forecasts -60.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: